NTRA News and Press, Natera Inc. From 02/05/24

Study shows ctDNA positivity is the most prognostic factor, demonstrating the potential for Signatera to redefine adjuvant treatment pathways in endometrial cancer Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Gynec...

2024-02-04 10:07:53 ET Summary Today, we revisit NeoGenomics, a cancer genetics testing company,. The company is making progress around delivering sales growth and reducing losses.  The company has a potential new problem on the litigation front, however. What's ahead for...

Clinical management was altered in 100% of patients with a Signatera positive result Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in The Journal of Thoracic and Cardiovascular Surgery demonstrating the ability of Na...

2024-01-29 09:29:24 ET More on CareDx CareDx's Turmoil: Risks Appear Priced In Circling Back On CareDx, Can The Rally Continue CareDx, Inc (CDNA) Q3 2023 Earnings Call Transcript CareDX drops after jury votes in favor of Natera in patent fight (update) ...

Liability for future sales to be determined Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of Natera in its patent infringement case a...

2024-01-26 13:32:36 ET More on CareDx, Natera, etc. CareDx's Turmoil: Risks Appear Priced In Natera: Squeezing The Last Drop From NIPT Growth Engine Circling Back On CareDx, Can The Rally Continue Invitae offloads reproductive health assets to Natera ...

AMPLIFY-201, a phase I trial evaluating treatment response to the ELI-002 vaccine, is the first study to read out using ctDNA to enroll and monitor patients with solid tumors PANDA study shows ctDNA status in patients with gastric and gastroesophageal cancers is strongly associated with r...

2024-01-22 11:29:07 ET More on S&P 500 Index: S&P 500 Sets New Record High As Investors Potentially Shift Focus To Q2 2024 Market Rally Met With Outflows S&P 500: The 'Pump' Is Underway - Watch Out For The 'Dump' S&P won't get the helping hand...

2024-01-22 07:51:11 ET More on Natera, Invitae, etc. Stocks To Watch: Energy Market Drama And Financial Earnings Headline Holiday Week Natera: Squeezing The Last Drop From NIPT Growth Engine Invitae Corporation 2023 Q3 - Results - Earnings Call Presentation C...

Invitae Completes Sale of Reproductive Health Assets to Natera PR Newswire SAN FRANCISCO , Jan. 22, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health as...